Acute extrapyramidal symptoms after the use of non-psychotropic drugs –⁠ a case report in clinical practice

Czech version

Authors: Jiří Smyčka ¹; Veronika Krejčí ^2,3; Tereza Uhrová ⁴; Tomáš Petr ¹; Lucie Kališová ^1,4
Authors‘ workplace: Psychiatrické oddělení, ÚVN – VoFN Praha ¹; Oddělení klinické farmacie, ÚVN – VoFN Praha ²; Farmakologický ústav, 1. LF UK a VFN v Praze ³; Neurologická klinika 1. LF UK a VFN v Praze ⁴
Published in: Čes. a slov. Psychiat., 121, 2025, No. 3, pp. 145-150.
Category: Case Report
doi: https://doi.org/10.48095/cccsp202512

Overview

This case report is from clinical practice about the development of an acute extrapyramidal state in a patient in outpatient psychiatric care who did not use pharmaceuticals that can cause extrapyramidal side effects. An overview of nonpsychiatric drugs that can cause extrapyramidal side effects and a description of the mechanism of their action are presented. Recommendation for treatment is supplemented. The necessity of gathering detailed anamnesis and a differential diagnosis is highlighted. This case report aims to broaden knowledge about these problems, which could enable quick diagnostics and treatment in clinical practice.

Keywords:

extrapyramidal side effects – thiethylperazine – extrapyramidal side effects treatment

Sources

1. Souhrn údajů o přípravku SPC Torecan. Dostupné online z SÚKL –⁠ Oficiální stránky Státního ústavu pro kontrolu léčiv, 27. 1. 2025.

2. Rissardo JP, Vora N, Mathew B et al. Overview of movement disorders secondary to drugs. Clinics and Practice 2023; 13 (4): 959–976. doi: 10.3390/clinpract13040087.

3. Briani C, Cagnin A, Chierichetti F et al. Thiethylperazine‐induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade. Eur J Neurol 2004; 11 (10): 709–710. doi: 10.1111/j.1468-1331.2004.00844.x.

4. Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. Neurol Clin 2014; 33 (1): 153–174. doi: 10.1016/j.ncl.2014.09.011.

5. Burkhard PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 2013; 20: S108–S112. doi: 10.1016/s1353-8020 (13) 70027-0.

6. Susatia F, Fernandez HH. Drug-induced parkinsonism. Curr Treat Options Neurol 2009; 11 (3): 162–169. doi: 10.1007/s11940-009-0019-3.

7. Uhrová T, Roth J (eds). Nežádoucí účinky antipsychotik. In: Neuropsychiatrie. Maxdorf; 2020 : 478–479.

8. Baláž M, Kašpárek T. Extrapyramidové účinky léčiv –⁠ minimum pro farmaceuty. Prakt Lékaren 2017; 13 (4): 151–155.

9. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394 : 939–951.

10. Mohr P (ed). Klinická psychofarmakologie. Maxdorf 2020.

11. Bondon‐Guitton E, Perez‐Lloret S, Bagheri H, et al. Drug‐induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord 2011; 26 (12): 2226–2231. doi: 10.1002/mds.23828.

12. Savica R, Grossardt BR, Bower JH et al. Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study. Mov Disord 2016; 32 (2): 227–234. doi: 10.1002/mds.26839.

13. De Germay S, Montastruc F, Carvajal A et al. Drug-induced parkinsonism: revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord 2019; 70 : 55–59. doi: 10.1016/j.parkreldis.2019.12.011.

14. López-Sendón JL, Mena MA, De Yébenes JG. Drug-Induced parkinsonism in the elderly. Drugs Aging 2012; 29 (2): 105–118. doi: 10.2165/11598540-000000000-00000.

15. Wenning GK, Kiechl S, Seppi K et al. Prevalence of movement disorders in men and women aged 50–89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005; 4 (12): 815–820. doi: 10.1016/s1474-4422 (05) 70226-x.

16. Kim S, Yu YM, Kwon J, et al. Trimetazidine use and the risk of parkinsonism: a Nationwide Population-Based Study. Int J Environ Res Public Health 2020; 17 (19): 7256. doi: 10.3390/ijerph17197256.

17. Miguel R, Correia AS, Bugalho P. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine. J Parkinsons Dis 2014; 4 (4): 645–649. doi: 10.3233/jpd-140414.

18. Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 1979; 28 (14): 2161–2165. doi: 10.1016/0006-2952 (79) 90198-9.

19. Souhrn údajů o přípravku SPC Akineton. Dostupné online z SÚKL –⁠ Oficiální stránky Státního ústavu pro kontrolu léčiv, 27. 1. 2025.

20. Ustohal L, Baláž M. Léčba EPS –⁠ akutní a tardivní dystonie a dyskineze. Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2018. Dostupné online na postupy-pece.psychiatrie.cz.

MUDr. Jiří Smyčka

Psychiatrické oddělení ÚVN –⁠ VoFN Praha

U Vojenské nemocnice 1200

169 02 Praha 6

e-mail: smycka.jiri@uvn.cz